| Aug 28 |
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
|
| Aug 24 |
We Think Cullinan Therapeutics (NASDAQ:CGEM) Can Afford To Drive Business Growth
|
| Aug 8 |
Cullinan Therapeutics GAAP EPS of -$0.75
|
| Aug 8 |
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
| Jun 9 |
Checking Into Cullinan Therapeutics
|
| Jun 4 |
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green
|
| Jun 3 |
Cullinan Therapeutics announces success for zipalertinib as combo therapy
|
| Jun 1 |
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
|
| May 24 |
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
|
| May 23 |
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
|
